ICECP™ Cancer Cell Panel Screening

Access 600+ cancer cell lines, including 100+ engineered knockout, knock-in and drug-resistant lines. Specialized panels ↗ are also available for DNA repair and synthetic-lethality research ↗.

2D and 3D CellTiter-Glo viability assays can be combined with colony formation, cell-cycle, apoptosis and combination-study endpoints.

RNA sequencing and bioinformatics analysis can help investigate drug response and resistance mechanisms.

Programs can transition to CDX studies using models derived from relevant cell lines.

Plate formats: 96-well or 384-well plates. Readouts: CellTiter-Glo, CyQUANT, Hoechst or Ki67. Serum: 10% FBS or 2–5% FBS, according to the study design.

Dose response: typically 10 doses for IC50 or GI50 studies, in duplicate. Treatment duration may be 3, 5, 7 days or longer, with at least two cell-doubling times where appropriate.

Study documentation includes methods and testing conditions, quality-control metrics such as Z′ factor, signal-to-window ratio, CV% and reference-compound data, plus inhibition values, curve fitting and IC50 results where applicable.

Programs can be extended with combination studies, target-engagement assays, apoptosis assays, cell-cycle analysis, protein-phosphorylation assays and xenograft models.

RNA-seq analysis of drug-resistant cell lines can provide differential-gene-expression information, enrichment pathways and characteristic gene profiles.

Specialized DDR, RAS, EGFR and HER2 panels can support mechanism-of-action studies and drug-sensitivity testing.